簡(jiǎn)介:PHA-665752是ATP競(jìng)爭(zhēng)性c-Met選擇性抑制劑,IC50為9 nM,比對(duì)RTKs和STKs的抑制性高50倍。
PHA-665752物理化學(xué)性質(zhì):
密度 |
1.4±0.1 g/cm3 |
沸點(diǎn) |
890.2±65.0 °C at 760 mmHg |
分子式 |
C32H34Cl2N4O4S |
分子量 |
641.608 |
閃點(diǎn) |
492.2±34.3 °C |
精確質(zhì)量 |
640.1678 |
PSA |
110.96 |
LogP |
4 |
外觀性狀 |
light yellow to light brown |
蒸汽壓 |
0.0±0.3 mmHg at 25°C |
折射率 |
1.656 |
儲(chǔ)存條件 |
Store at +4°C |
水溶解性 |
DMSO: ≥20mg/mL |
PHA-665752詳細(xì)介紹:
中文名稱: |
(2R)-1-[[5-[(Z)-[5-[[(2,6-二氯苯基)甲基]磺酰]-1,2-二氫-2-氧代-3H-吲哚-3-亞基]甲基]-2,4-二甲基-1H-吡咯-3-基]羰基]-2-(1-吡咯烷甲基)吡咯烷 |
中文別名: |
(2R)-1-[[5-[(Z)-[5-[[(2,6-二氯苯基)甲基]磺酰]-1,2-二氫-2-氧代-3H-吲哚-3-亞基]甲基]-2,4-二甲基-1H-吡咯-3-基]羰基]-2-(1-吡咯烷甲基)吡咯烷;(2R)-1-[[5-[(Z)-[5-[[(2,6-二氯苯基)甲基]磺酰]-1,2-二氫-2-氧代-3H-吲哚-3-亞基]甲基]-2,4-二甲基-1H-吡咯-3-基]羰基]-2-(1-吡咯...;PHA-665752 抑制劑 |
英文名稱: |
PHA-665752 |
英文別名: |
PHA665752;(2R)-1-[[5-[(Z)-[5-[[(2,6-Dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)pyrrolidine;PHA-665752;(2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-P;PHA-665752 (PHA 665752);PHA-665752 hydrate;(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one;PHA 665752;0VXU5T5R3J;(R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one;(2R)-1-[[5-[(Z)-[5-[[(2,6-Dichlorophenyl)methyl]su |
CAS號(hào): |
477575-56-7 |
分子式: |
C32N4O4SCL2H34 |
分子量: |
641.61 |
詳細(xì)描述 |
博飛美科提供477575-56-7,PHA-665752,Medlife,上海現(xiàn)貨。 Medlife,致力于提供高品質(zhì)、高性價(jià)比小分子化合物的產(chǎn)品。 Medlife小分子化合物大量庫(kù)存,提供超過(guò)2萬(wàn)種的抑制劑、激動(dòng)劑、拮抗劑等產(chǎn)品,是藥物及疾病研究的重要原料供應(yīng)商。 c-Met的ATP競(jìng)爭(zhēng)性、有效的、選擇性抑制劑,PHA-665752是ATP競(jìng)爭(zhēng)性c-Met選擇性抑制劑,IC50為9 nM,比對(duì)RTKs和STKs的抑制性高50倍。 查詢關(guān)鍵詞:“477575-56-7,PHA-665752,PC16006,Medlife,上海現(xiàn)貨”。 |
PHA-665752參考文獻(xiàn):
[1]. Christensen JG, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res, 2003, 63(21), 7345-7355.
[2]. Ma PC, et al. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res, 2005, 11(6), 2312-2319.
[3]. Puri N, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res, 2007, 67(8), 3529-3534.
[4]. Tsubaki M, et al. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells. Oncotarget. 2017 Jun 13;8(24):38717-38730.
產(chǎn)品技術(shù)規(guī)格說(shuō)明書由上海創(chuàng)賽科技有限公司收集整理,僅作參考使用。